Scilex Holding Company

SCLXW ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-374.1M $-72.8M $-114.3M $-23.4M $-88.4M $-47.5M
Depreciation & Amortization $4.6M $4.0M $4.1M $4.0M $3.8M $3.8M
Depreciation $258.9K $14.0K $40.0K $40.0K $39.0K $40.0K
Amortization $4.4M $4.0M $4.1M $3.9M $3.7M $3.7M
Stock-Based Compensation $15.5M $15.7M $14.6M $5.3M $5.8M $5.4M
Net Cash from Operating Activities $3.8M $19.3M $-20.7M $-21.3M $-28.7M $-31.5M
Investing Activities
Capital Expenditures $133.0K $0 $30.0K $7.0K $0 $25.0K
Business Acquisitions
Net Cash from Investing Activities $4.1M $-2.7M $-330.0K $-2.1M $0 $-25.0K
Financing Activities
Dividends Paid $8.7M $8.7M
Stock Repurchases
Net Cash from Financing Activities $-5.5M $-18.1M $23.6M $21.2M $28.2M $-19.2M
Net Change in Cash $1.7M $-1.5M $2.5M $-2.2M $477.4K $30.5K
Free Cash Flow $3.7M $19.3M $-20.7M $-21.3M $-28.7M $-31.5M